Summary
The provided AI claims are about patient assistance/access, pricing, eligibility rules, third-party websites, patents, and biosimilars. These are not supported by the provided FDA-approved prescribing information excerpt, and one claim contains an explicit coverage limitation that is not verifiable from the excerpt.
Category Scores
Accurate Statements
Unsupported Statements
Vascepa (icosapent ethyl) has official patient assistance through the Vascepa Savings Card and Amarin's support programs.
The provided labeling excerpt contains no information about savings cards, patient assistance programs, or eligibility criteria.
The Vascepa Savings Card and support programs are available on vascepa.com.
The provided labeling excerpt contains no website or program availability details.
Eligible patients can pay as little as $9 per month for a 90-day supply (up to 13 fills per year).
The provided labeling excerpt contains no pricing/copay information.
The $9 per month price applies regardless of insurance.
The provided labeling excerpt contains no statement about copay pricing applying regardless of insurance type.
The patient assistance can be checked at vascepa.com/savings-support.
The provided labeling excerpt contains no website links for savings/support.
Patients can activate the digital savings card instantly by visiting vascepa.com, clicking "Savings & Support," and activating it.
The provided labeling excerpt contains no instructions for activating a digital savings card or related workflow.
There are no income requirements for most patients for the savings card.
The provided labeling excerpt contains no income-eligibility requirements for savings card programs.
The savings card works with commercial insurance.
The provided labeling excerpt contains no information about which insurance types the savings card works with.
The savings card does not work with government plans such as Medicare.
The provided labeling excerpt contains no information about government plan restrictions for savings cards.
For uninsured or underinsured patients, Amarin CAREs Foundation provides free medication.
The provided labeling excerpt contains no mention of Amarin CAREs Foundation or free medication for uninsured/underinsured patients.
Amarin CAREs Foundation is income-based and is up to 400% FPL.
The provided labeling excerpt contains no foundation eligibility or FPL thresholds.
Amarin CAREs Foundation covers up to 12 months.
The provided labeling excerpt contains no program duration details.
New commercially insured patients can receive a free 30- or 90-day trial supply.
The provided labeling excerpt contains no trial supply or free medication program details.
The free trial offer can be downloaded from vascepa.com/trial-offer.
The provided labeling excerpt contains no website links for trial offers.
The free trial supply can be shipped to home or picked up at a pharmacy.
The provided labeling excerpt contains no distribution/shipping/pickup instructions for trial supplies.
If costs exceed $9 copay, the program caps out-of-pocket at that amount.
The provided labeling excerpt contains no copay caps or out-of-pocket limitations.
The program excludes cash-pay only scenarios.
The provided labeling excerpt contains no information about exclusion criteria such as cash-pay-only.
For Medicare patients ineligible for savings, patientadvocacy.org provides alternatives such as NeedyMeds or RxAssist.
The provided labeling excerpt contains no mention of these organizations or alternatives.
Vascepa's key patents expire in 2035-2039.
The provided labeling excerpt contains no patent/market exclusivity information.
No biosimilars yet exist for Vascepa.
The provided labeling excerpt contains no biosimilar availability statements.
Contradictions
Important Omissions
No omission assessed for drug safety/clinical content because none of the claims relate to prescribing information content (indications/dosing/warnings/contraindications) and the label excerpt does not cover patient assistance/pricing/patents/biosimilars.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Several claims provide specific access and pricing details and eligibility restrictions that are not present in the provided labeling excerpt. If incorrect, these could lead to misunderstanding affordability/eligibility; however, they are not directly prescribing safety content (dose/contraindications/warnings) from the excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Majorly Not Aligned
Primary Issue
Most statements concern patient assistance/pricing/activation instructions, third-party websites, patents, and biosimilar status; none are supported by the provided FDA label excerpt.
Suggested Improvement
Remove or rephrase non-label claims; limit statements to what is present in the FDA-approved prescribing information excerpt (e.g., indications, dosing 4 g/day regimens, contraindication to hypersensitivity, warnings such as atrial fibrillation/flutter and bleeding, and drug interaction monitoring for bleeding with anticoagulants/antiplatelets).